Indaptus Therapeutics (NASDAQ:INDP) Posts Quarterly Earnings Results, Beats Expectations By $1.55 EPS

Indaptus Therapeutics (NASDAQ:INDP) released its earnings results on Thursday. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($1.57) by $1.55, Zacks reports.

Indaptus Therapeutics Stock Performance

INDP traded up $0.04 on Thursday, hitting $1.06. 92,854 shares of the company were exchanged, compared to its average volume of 111,264. The business’s fifty day moving average is $2.57 and its 200 day moving average is $2.22. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $8.57. The firm has a market capitalization of $120.03 million, a P/E ratio of -0.07 and a beta of 1.18.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on INDP shares. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is currently owned by hedge funds and other institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.